Piper Jaffray Upgrades Acadia Pharmaceuticals (ACAD) to Overweight
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $28.63 +1.38%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Piper Jaffray upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Overweight with a price target of $19.00 (from $5.00).
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.
Shares of Acadia Pharmaceuticals closed at $7.97 yesterday.
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.
Shares of Acadia Pharmaceuticals closed at $7.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
- Shimao Property Holdings Limited (813:HK) (SIOPF) PT Lowered to HK$0.05 at JPMorgan
- LG Electronics India (LGEL:IN) PT Raised to INR1,983 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
